Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlioMET: 11C-methionine PET/CT in Glioblastoma Multiforme With Rapid Early Progression
NCT05608395Phase 2Completed
- Sponsor
- Masaryk Memorial Cancer Institute
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of L-(11C) methionine in glioblastoma multiforme (GBM) (2 arms), sponsored by Masaryk Memorial Cancer Institute. Primary endpoint: Progression-Free Survival at 44 months. Started Dec 2020; status: completed.
02
Drugs
L-(11C) methionine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05608395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608395.